299 related articles for article (PubMed ID: 27750032)
21. Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease.
Perneczky R; Alexopoulos P;
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S425-S429.e1. PubMed ID: 24239250
[TBL] [Abstract][Full Text] [Related]
22. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
23. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
[TBL] [Abstract][Full Text] [Related]
24. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
Savage MJ; Holder DJ; Wu G; Kaplow J; Siuciak JA; Potter WZ;
J Alzheimers Dis; 2015; 46(2):431-40. PubMed ID: 25790831
[TBL] [Abstract][Full Text] [Related]
25. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life.
Cirrito JR; May PC; O'Dell MA; Taylor JW; Parsadanian M; Cramer JW; Audia JE; Nissen JS; Bales KR; Paul SM; DeMattos RB; Holtzman DM
J Neurosci; 2003 Oct; 23(26):8844-53. PubMed ID: 14523085
[TBL] [Abstract][Full Text] [Related]
26. BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism.
Stern AL; Ghura S; Gannon PJ; Akay-Espinoza C; Phan JM; Yee AC; Vassar R; Gelman BB; Kolson DL; Jordan-Sciutto KL
J Neurosci; 2018 May; 38(18):4288-4300. PubMed ID: 29632166
[TBL] [Abstract][Full Text] [Related]
27. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.
May PC; Willis BA; Lowe SL; Dean RA; Monk SA; Cocke PJ; Audia JE; Boggs LN; Borders AR; Brier RA; Calligaro DO; Day TA; Ereshefsky L; Erickson JA; Gevorkyan H; Gonzales CR; James DE; Jhee SS; Komjathy SF; Li L; Lindstrom TD; Mathes BM; Martényi F; Sheehan SM; Stout SL; Timm DE; Vaught GM; Watson BM; Winneroski LL; Yang Z; Mergott DJ
J Neurosci; 2015 Jan; 35(3):1199-210. PubMed ID: 25609634
[TBL] [Abstract][Full Text] [Related]
28. Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.
Pettus LH; Bourbeau MP; Bradley J; Bartberger MD; Chen K; Hickman D; Johnson M; Liu Q; Manning JR; Nanez A; Siegmund AC; Wen PH; Whittington DA; Allen JR; Wood S
J Med Chem; 2020 Mar; 63(5):2263-2281. PubMed ID: 31589043
[TBL] [Abstract][Full Text] [Related]
29. Investigational BACE inhibitors for the treatment of Alzheimer's disease.
Imbimbo BP; Watling M
Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331
[No Abstract] [Full Text] [Related]
30. Comparison of two different methods for measurement of amyloid-β peptides in cerebrospinal fluid after BACE1 inhibition in a dog model.
Borghys H; Jacobs T; Van Broeck B; Dillen L; Dhuyvetter D; Gijsen H; Mercken M
J Alzheimers Dis; 2014; 38(1):39-48. PubMed ID: 23948925
[TBL] [Abstract][Full Text] [Related]
31. Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages.
Devi L; Ohno M
Neuroscience; 2015 Oct; 307():128-37. PubMed ID: 26314636
[TBL] [Abstract][Full Text] [Related]
32. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
[TBL] [Abstract][Full Text] [Related]
33. The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease.
Liang ZM; Peng YH; Chen Y; Long LL; Luo HJ; Chen YJ; Liang YL; Tian YH; Li SJ; Shi YS; Zhang XM
Nucleic Acid Ther; 2019 Dec; 29(6):359-366. PubMed ID: 31513457
[TBL] [Abstract][Full Text] [Related]
34. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease.
Wu G; Sankaranarayanan S; Wong J; Tugusheva K; Michener MS; Shi X; Cook JJ; Simon AJ; Savage MJ
J Neurosci Res; 2012 Dec; 90(12):2247-58. PubMed ID: 22987781
[TBL] [Abstract][Full Text] [Related]
35. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice.
McConlogue L; Buttini M; Anderson JP; Brigham EF; Chen KS; Freedman SB; Games D; Johnson-Wood K; Lee M; Zeller M; Liu W; Motter R; Sinha S
J Biol Chem; 2007 Sep; 282(36):26326-34. PubMed ID: 17616527
[TBL] [Abstract][Full Text] [Related]
36. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
[TBL] [Abstract][Full Text] [Related]
37. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
38. Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo.
Kim ML; Zhang B; Mills IP; Milla ME; Brunden KR; Lee VM
J Neurosci; 2008 Nov; 28(46):12052-61. PubMed ID: 19005070
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation.
Brendel M; Jaworska A; Overhoff F; Blume T; Probst F; Gildehaus FJ; Bartenstein P; Haass C; Bohrmann B; Herms J; Willem M; Rominger A
Theranostics; 2018; 8(18):4957-4968. PubMed ID: 30429879
[TBL] [Abstract][Full Text] [Related]
40. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
